Article
Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma
Eruptive keratoacanthomas (KAs) are a rare buttransient adverse effect of programmed cell death protein 1 (PD-1) inhibitor therapy.
Greg K. Sakamoto, MD
Eruptive keratoacanthomas (KAs) are a rare buttransient adverse effect of programmed cell death protein 1 (PD-1) inhibitor therapy.